Cancer is Rising Among Women: Early Detection of Lung Cancer
Cancer is Rising Among Young Women: Early Detection of Lung Cancer Lung cancer rates are rising among younger women, making early detection more critical than ever. There is an alarming trend of increased diagnoses in women and it emphasizes the importance of early detection for successful treatment. Innovative technologies, like Biomark Diagnostics’ liquid biopsy, can […]
Cancer Prevention: 5 Actionable Steps
Cancer Prevention: 5 Actionable Steps Take control of your health and reduce your cancer risk through simple lifestyle changes! We present five actionable steps for cancer prevention, including quitting inhalants, limiting alcohol and sugary drinks, increasing physical activity, and making healthy food choices. We also discuss the importance of early cancer detection through regular checkups […]
Form 7 Monthly Progress Report December 2025
Form 7 Monthly Progress Report December 2024 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 90,886,229 January 3, 2025 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BioMark’s Liquid Biopsy Platform Takes A Major Step Forward in Breast Cancer Diagnosiswith AI-powered ER Status Prediction
BioMark’s Liquid Biopsy Platform Takes A Major Step Forward in Breast Cancer Diagnosis with AI-powered ER Status Prediction BioMark Expands Its Liquid Biopsy Platform Receptor Status for Breast Cancer Vancouver, British Columbia – (December 10, 2024) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leader in liquid biopsy tests for early […]
Form 7 Monthly Progress Report November 2024
Form 7 Monthly Progress Report December 2024 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 90,886,229 December 2th, 2024 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BioMark Expands its Liquid Biopsy Platform with two Groundbreaking Publications in Breast Cancer Detection
BioMark Expands its Liquid Biopsy Platform with two Groundbreaking Publications in Breast Cancer Detection BioMark Strengthens Liquid Biopsy Platform for Breast Cancer Detection Vancouver, British Columbia – (November 5, 2024) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, today announced significant […]
Form 7 Monthly Progress Report October 2024
Form 7 Monthly Progress Report November 2024 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 90,886,229 November 4th, 2024 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
Form 7 Monthly Progress Report September 2024
Form 7 Monthly Progress Report October 2024 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 90,886,229 October 3rd, 2024 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify Biomarkers for NEN
BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify Biomarkers for NEN BioMark’s Liquid Biopsy Technology Offers Promise for NEN Diagnosis Vancouver, British Columbia – (September 24, 2024) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, […]
BioMark Diagnostics Completes Testing of Over 5,400 subjects as Part of a Validation Study for Early Lung Cancer Detection
BioMark Diagnostics Completes Testing of Over 5,400 subjects as Part of a Validation Study for Early Lung Cancer Detection Largest Clinical Study Validating a Metabolite-based Assay for Lung Cancer Screening Vancouver, British Columbia – (September 10, 2024) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for […]